Display options
Cite
Ng CK, Gstöttner M, Gmeiner R. Intracardiac electrophysiological effects of lorcainide in man. Eur J Clin Pharmacol. 1979;15(4):241-7doi: 10.1007/BF00618512.
Ng, C. K., Gstöttner, M., & Gmeiner, R. (1979). Intracardiac electrophysiological effects of lorcainide in man. European journal of clinical pharmacology, 15(4), 241-7. https://doi.org/10.1007/BF00618512
Ng, C K, et al. "Intracardiac electrophysiological effects of lorcainide in man." European journal of clinical pharmacology vol. 15,4 (1979): 241-7. doi: https://doi.org/10.1007/BF00618512
Ng CK, Gstöttner M, Gmeiner R. Intracardiac electrophysiological effects of lorcainide in man. Eur J Clin Pharmacol. 1979 May 21;15(4):241-7. doi: 10.1007/BF00618512. PMID: 477708.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Eur J Clin Pharmacol. 1979 May 21;15(4):241-7. doi: 10.1007/BF00618512.

Intracardiac electrophysiological effects of lorcainide in man.

European journal of clinical pharmacology

C K Ng, M Gstöttner, R Gmeiner

PMID: 477708 DOI: 10.1007/BF00618512

Abstract

The electrophysiological effects of lorcainide 1.25 or 2.5 mg/kg given iv over 2 or 4 min, were studied in 21 patients with normal and diseased impulse formation and conduction, by means of intracardiac recording and stimulation. Sinus rate and the effective atrial refractory period rose following both doses of lorcainide. The corrected sinus node recovery time rose only after lorcainide 2.5 mg/kg and then most markedly in patients with sinus node dysfunction. The P-A interval remained unchanged following the drug. The A-H interval during sinus rhythm, and the pooled A-H intervals during atrial pacing, increased slightly, and the functional and effective A-V nodal refactory period changed variably. Wenckebach periods above the bundle of His occurred at lower atrial pacing rates following both doses of lorcainide in 7 patients, at the same atrial pacing rate in 9 and at higher rates in 3. H-V intervals, pooled H-V intervals and QRS-width lengthened in all patients, most markedly in cases with a conduction delay below the His bundle, who had received lorcainide 2.5 mg/kg. Thus, lorcainide shares some electrophysiological properties with procainamide and aprindine. Higher doses should be used with caution in patients with pre-existing conduction delay below the bundle His.

References

  1. Am J Cardiol. 1976 Apr;37(5):724-31 - PubMed
  2. Arch Int Pharmacodyn Ther. 1978 Jan;231(1):104-30 - PubMed
  3. Circulation. 1972 Jan;45(1):140-58 - PubMed
  4. Am J Cardiol. 1973 Feb;31(2):277-81 - PubMed
  5. Br Heart J. 1976 Dec;38(12):1262-71 - PubMed
  6. Circulation. 1969 Jan;39(1):13-8 - PubMed
  7. Circulation. 1971 Jul;44(1):59-66 - PubMed
  8. Am J Cardiol. 1974 May 6;33(5):596-603 - PubMed
  9. Acta Cardiol. 1974;Suppl 18:251-67 - PubMed
  10. Circulation. 1970 Jan;41(1):77-87 - PubMed
  11. Am Heart J. 1972 Dec;84(6):778-86 - PubMed
  12. Arch Int Pharmacodyn Ther. 1977 Dec;230(2):225-34 - PubMed
  13. Circ Res. 1970 Sep;27(3):345-59 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources